UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): February 3, 2015

 

SECOND SIGHT MEDICAL PRODUCTS, INC.
(Exact Name of Registrant as Specified in Its Charter)
 
California
(State or Other Jurisdiction of Incorporation)
 
  333-198073     02-0692322  
  (Commission File Number)     (IRS Employer Identification No.)  
   

 

12744 San Fernando Road, Building 3
Sylmar, California 91342

(Address of Principal Executive Offices)
 
(818) 833-5000
(Registrant's Telephone Number, Including Area Code)
 
 
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

ITEM 8.01. OTHER ITEMS

 

On February 3, 2015 the Company issued a press release announcing that the German national system, which provides health insurance to 90% of the country’s population, Das Institut für das Entgeltsystem im Krankenhaus (InEK) GmbH, has renewed Status 1 for the Argus® II Retinal Prosthesis System under the Neue Untersuchungs und Behandlungsmethoden innovation program (NUB) for one year. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by this reference.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

 

(d) Exhibits

 

Exhibit No. Description
   
99.1 Press Release issued February 3, 2015

 

 

2
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

 

  SECOND SIGHT MEDICAL PRODUCTS, INC.
   
  By:  /s/ Thomas B. Miller
   

By: Thomas B. Miller

Chief Financial Officer

 

 

 

 

 

Date: February 5, 2015

 

 

3